CSL (OTCMKTS:CSLLY) Reaches New 12-Month Low – What’s Next?

CSL Limited Sponsored ADR (OTCMKTS:CSLLY) shares hit a new 52-week low during trading on Monday . The stock traded as low as $51.9990 and last traded at $52.1535, with a volume of 54182 shares trading hands. The stock had previously closed at $54.02.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on CSLLY. Royal Bank Of Canada downgraded CSL from a “moderate buy” rating to a “hold” rating in a research report on Wednesday, February 11th. Canaccord Genuity Group raised CSL from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, October 28th. Finally, Zacks Research upgraded shares of CSL from a “strong sell” rating to a “hold” rating in a research note on Monday, December 29th. One research analyst has rated the stock with a Strong Buy rating and two have issued a Hold rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy”.

CSL Stock Performance

The company has a current ratio of 2.46, a quick ratio of 1.12 and a debt-to-equity ratio of 0.50. The stock’s fifty day simple moving average is $58.52 and its two-hundred day simple moving average is $63.35.

About CSL

CSL Limited (OTCMKTS: CSLLY) is a global biotechnology company headquartered in Melbourne, Australia that develops, manufactures and delivers a range of plasma-derived and recombinant therapeutics, vaccines and related services. Its principal businesses include CSL Behring, which focuses on specialty biotherapies for bleeding disorders, immune deficiencies, hereditary angioedema and other serious conditions; Seqirus, an influenza vaccine company formed following CSL’s acquisition of Novartis’ influenza vaccine business; and CSL Plasma, a network of plasma collection centers that supplies the raw material for many of its therapies.

The company’s product portfolio spans immunoglobulins, clotting factor concentrates, albumin and other protein-based treatments used in the management of chronic and acute rare diseases, as well as seasonal and pandemic influenza vaccines.